Autor: |
Rachael V. McCaleb, PharmD, BCPS, Jill T. Johnson, PharmD, BCPS |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
AACE Clinical Case Reports, Vol 5, Iss 1, Pp e82-e85 (2019) |
Druh dokumentu: |
article |
ISSN: |
2376-0605 |
DOI: |
10.4158/ACCR-2018-0295 |
Popis: |
ABSTRACT: Objective: Denosumab is a monoclonal antibody commonly used for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Hypocalcemia is a known adverse effect with denosumab, and we present an unusual case where 2 hypocalcemic events occurred after 1 denosumab treatment.Methods: A 76-year-old man recently diagnosed with prostate cancer with bone metastasis was given 120 mg denosumab subcutaneously due to extensive bone disease.Results: The patient experienced denosumab-induced hypocalcemia induced by a single denosumab dose which was resolved after 14 days of multiple doses of intravenous calcium gluconate and oral calcium and vitamin D replacement. However, the patient returned with acute kidney injury and severe hypocalcemia (corrected calcium of 6.9 mg/dL) without any additional dose of denosumab. The recovery following the second episode of hypocalcemia was much longer than the initial episode in this patient.Conclusion: To our knowledge, this is the first reported case of an additional episode of hypocalcemia following a single denosumab dose. This case highlights the importance of close monitoring of renal function and serum electrolytes following the resolution of denosumab-induced hypocalcemia.Abbreviations: 25(OH)D = 25-hydroxyvitamin D; AKI = acute kidney injury; CI = confidence interval; IV = intravenous; PTH = parathyroid hormone; SRE = skeletal-related event; ZA = zoledronic acid |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|